Every AI newsletter, investors ask on the investor interaction platform: does your company develop innovative traditional Chinese medicine? Does the management and board of directors have specific measures for the performance of the company’s share price in the secondary market?
Chongqing Pharscin Pharmaceutical Co.Ltd(002907) ( Chongqing Pharscin Pharmaceutical Co.Ltd(002907) . SZ) said on the investor interaction platform on April 1 that the company is not developing innovative traditional Chinese medicine for the time being. The company has actively arranged the innovative research and development of small molecule drugs. At present, four preclinical projects of innovative drugs related to cancer have been approved and promoted rapidly. The company also cut into the track of “special medical food” through investment, which is of far-reaching significance to the layout of the company in the field of general health.
